Frizzled‑2: A potential novel target for molecular pancreatic cancer therapy

Tomizawa,Minoru; Shinozaki,Fuminobu; Sugiyama,Takao; Yamamoto,Shigenori; Sueishi,Makoto; Yoshida,Takanobu

doi:10.3892/ol.2013.1681

Frizzled‑2: A potential novel target for molecular pancreatic cancer therapy

Authors:
- Minoru Tomizawa
- Fuminobu Shinozaki
- Takao Sugiyama
- Shigenori Yamamoto
- Makoto Sueishi
- Takanobu Yoshida
View Affiliations

Affiliations: Department of Gastroenterology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan, Department of Radiology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan, Department of Rheumatology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan, Department of Pediatrics, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan, Department of Internal Medicine, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan
Published online on: November 12, 2013 https://doi.org/10.3892/ol.2013.1681
Pages: 74-78

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, pancreatic cancer cell proliferation was analyzed following the suppression of frizzled (Fz)2 expression. Reverse transcription polymerase chain reaction (PCR) was performed using RNA isolated from pancreatic cancer cell lines, PANC‑1, NOR‑P1, PK‑45H, PK‑1, PK‑59, MIA‑Paca2 and KP4. A surgical specimen of pancreatic cancer was immunostained with antibodies specific to Fz2. Cell proliferation assays were performed with MIA‑Paca2 cells transfected with small interfering RNA (siRNA) or short hairpin RNA (shRNA) of Fz2. Fz2 was found to be expressed in all pancreatic cancer cell lines, with the exception of NOR‑P1. Immunostaining revealed that Fz2 was not expressed in normal pancreatic tissues, while it was expressed in pancreatic cancer cells. The expression levels of cyclin D1 were analyzed by quantitative PCR. The proliferation and expression of cyclin D1 were suppressed with the siRNA and shRNA of Fz2 in the MIA‑Paca2 cells. Therefore, Fz2 is a potential target for the molecular therapy of pancreatic cancer.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Mao C, Domenico DR, Kim K, Hanson DJ and Howard JM: Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg. 130:125–134. 1995. View Article : Google Scholar
3	Vogel I, Krüger U, Marxsen J, et al: Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor. Clin Cancer Res. 5:593–599. 1999.
4	Winter JM, Ting AH, Vilardell F, et al: Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res. 14:412–418. 2008. View Article : Google Scholar
5	Iovanna J, Mallmann MC, Gonçalves A, Turrini O and Dagorn JC: Current knowledge on pancreatic cancer. Front Oncol. 2:62012. View Article : Google Scholar
6	Asuthkar S, Rao JS and Gondi CS: Drugs in preclinical and early-stage clinical development for pancreatic cancer. Expert Opin Investig Drugs. 21:143–152. 2012. View Article : Google Scholar : PubMed/NCBI
7	Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M and Yoshida T: Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer. World J Gastroenterol. 16:1854–1858. 2010. View Article : Google Scholar
8	Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M and Yoshida T: Insulin-like growth factor I receptor involvement in proliferation of NOR-P1 cells in serum-free media. J Cell Biochem. 113:2714–2720. 2012. View Article : Google Scholar : PubMed/NCBI
9	Rajpathak SN, Gunter MJ, Wylie-Rosett J, et al: The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev. 25:3–12. 2009. View Article : Google Scholar : PubMed/NCBI
10	Katoh M and Katoh M: WNT signaling pathway and stem cell signaling network. Clin Cancer Res. 13:4042–4045. 2007. View Article : Google Scholar : PubMed/NCBI
11	Chen HJ, Hsu LS, Shia YT, Lin MW and Lin CM: The β-catenin/TCF complex as a novel target of resveratrol in the Wnt/β-catenin signaling pathway. Biochem Pharmacol. 84:1143–1153. 2012.
12	Wang HY, Liu T and Malbon CC: Structure-function analysis of Frizzleds. Cell Signal. 18:934–941. 2006. View Article : Google Scholar : PubMed/NCBI
13	Kirikoshi H, Sekihara H and Katoh M: Expression profiles of 10 members of Frizzled gene family in human gastric cancer. Int J Oncol. 19:767–771. 2001.PubMed/NCBI
14	Fujimoto T, Tomizawa M and Yokosuka O: SiRNA of frizzled-9 suppresses proliferation and motility of hepatoma cells. Int J Oncol. 35:861–866. 2009.PubMed/NCBI
15	Sagara N, Toda G, Hirai M, Terada M and Katoh M: Molecular cloning, differential expression, and chromosomal localization of human frizzled-1, frizzled-2, and frizzled-7. Biochem Biophys Res Commun. 252:117–122. 1998. View Article : Google Scholar
16	Zeng G, Germinaro M, Micsenyi A, et al: Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia. 8:279–289. 2006. View Article : Google Scholar : PubMed/NCBI
17	Jones S, Zhang X, Parsons DW, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar
18	White BD, Chien AJ and Dawson DW: Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology. 142:219–232. 2012.
19	Pujal J, Capellá G and Real FX: The Wnt pathway is active in a small subset of pancreas cancer cell lines. Biochim Biophys Acta. 1762:73–79. 2006. View Article : Google Scholar : PubMed/NCBI
20	Luo Y, Qiu Z, Tian L, et al: Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma. Hum Pathol. 44:69–76. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wang JC, Thiere M, Henne-Bruns D, Knippschild U and Kornmann M: Inhibition of pancreatic cancer cell growth in vivo using a tetracycline-inducible cyclin D1 antisense expression system. Pancreas. 42:141–148. 2012. View Article : Google Scholar
22	Heidegger I, Pircher A, Klocker H and Massoner P: Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol Ther. 11:701–707. 2011. View Article : Google Scholar : PubMed/NCBI